

## ICOAT MEDICAL'S PRECLINICAL RESULTS PRESENTED AT THE PRESTIGIOUS WORLD BIOMATERIALS CONGRESS IN SOUTH KOREA

iCoat Medical, a clinical stage pharmaceutical company focusing on reducing and preventing ischemia reperfusion injuries (IRI) during organ transplantation, today announced that its Chief Medical Officer Dr. Alireza Biglarnia was recently invited as Keynote speaker to present the company's preclinical results with the lead drug candidate iCM012 at the prestigious World Biomaterials Congress (WBC) in Daegu, South Korea.

Dr Biglarnia's Keynote speech, titled *Enhancing kidney transplantation: Addressing ischemia-reperfusion injury through ex vivo cell surface engineering with a novel amphiphilic polymer*, focused on the company's completed preclinical program with iCM012 in deceased-donor kidney transplantation.

"It was very exciting to be able to present our preclinical results with iCM012 to the scientific community. We are now in clinical development and look forward to the start the Phase 2b study EMPIRe, which follows the successful completion of the first-in-man study ATMIRe," said Dr. Biglarnia.

The one-year follow-up part of the Phase 1/2a clinical study ATMIRe was recently completed, and the encouraging outcome is planned for presentation at a scientific conference later this year.

The randomised, controlled, double-blind phase 2b efficacy study EMPIRe, which is planned to start in 2024, will include approximately 100 patients and be performed at selected high-quality sites in Europe and the U.S. The potential for conditional approval, given sufficiently convincing data generated by the Phase 2b study, will be discussed with the regulatory authorities.

**For more information, please contact:**

Peder Waern, CEO – iCoat Medical AB

E-mail: [peder.waern@icoatmedical.com](mailto:peder.waern@icoatmedical.com)

**About iCoat Medical**

iCoat Medical is a clinical stage, pharmaceutical company focusing on reducing and preventing ischemia reperfusion injuries by developing novel pharmaceutical products. The company is one of the world's leading R&D-centered organizations within innate immunology and is systematically expanding its pipeline using its proprietary coating-technology platform. iCoat Medical's lead candidate iCM012 is developed to improve the outcome of organ transplantations. The company's unique ex-vivo coating of the grafts has the ambition of being an integral part in the transplant procedures of tomorrow. iCoat Medical has operations in Uppsala, Lund, and Malmö, and is headquartered in Stockholm. For more information, please visit <https://www.icoatmedical.com/sv/>.

**Attachments**

---

**[iCoat Medical's preclinical results presented at the prestigious World Biomaterials Congress in South Korea](#)**